|
The Company’s vaccine candidate for the treatment of prostate cancer is designed to express sequences that control immunity to prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP).
A Phase I/II safety and tolerability study in 18 male patients with non-metastatic as well as hormone-insensitive prostate cancer has begun enrolment in the US. Secondary objectives of the trial include examining the ability of the vaccine to induce prostate antigen-specific immune responses, as well as clinical anti-tumor activity. Preliminary data is expected during second half year 2009.
|
